Plain-English translation of NCT06389305 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing therapy — a treatment made from your own immune cells — to see if it can help rescue CAR-T cell therapy when it stops working in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. CAR-T therapy is a powerful cancer treatment that trains your immune cells to fight leukemia, but sometimes these trained cells become exhausted and stop working. This study will compare patients who receive the new treatment with those who receive standard care to see if CIK cells can revive your CAR-T cells and help you stay in remission longer.
CAR-T cell therapy has helped many leukemia patients, but in some cases the CAR-T cells lose their ability to fight the cancer within months. This trial exists to find a way to rescue CAR-T therapy when it's failing, which could give hope to patients whose leukemia has come back or is no longer responding to treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of three groups: a control group, a group receiving therapy, or a group receiving a newer form of therapy using messenger RNA. Your participation will involve hospital visits where doctors will collect your blood to grow the immune cells, give you the treatment infusions, and monitor your health with blood tests and scans. The study team will follow you to see how long you stay in remission and how well the CIK cells help your CAR-T therapy work.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China